SGEN, SNY And REGN, 3 Health Care Stocks Pushing The Sector Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 15 points (0.1%) at 16,035 as of Monday, Dec. 9, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,480 issues advancing vs. 1,397 declining with 175 unchanged.

The Health Care sector currently is unchanged today versus the S&P 500, which is up 0.3%. On the negative front, top decliners within the sector include Edwards Life ( EW), down 5.6%, and Biogen Idec ( BIIB), down 0.8%. Top gainers within the sector include Celgene Corporation ( CELG), up 4.2%, Bristol-Myers Squibb Company ( BMY), up 1.9%, Gilead ( GILD), up 1.3%, Cigna ( CI), up 1.2% and WellPoint ( WLP), up 1.0%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Seattle Genetics ( SGEN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Seattle Genetics is down $2.50 (-5.6%) to $41.85 on heavy volume. Thus far, 751,148 shares of Seattle Genetics exchanged hands as compared to its average daily volume of 838,000 shares. The stock has ranged in price between $41.60-$44.99 after having opened the day at $44.50 as compared to the previous trading day's close of $44.35.

Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S. Seattle Genetics has a market cap of $5.4 billion and is part of the drugs industry. Shares are up 91.4% year to date as of the close of trading on Friday. Currently there are 3 analysts that rate Seattle Genetics a buy, 2 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Seattle Genetics as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and feeble growth in its earnings per share. Get the full Seattle Genetics Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Sanofi ( SNY) is down $0.50 (-1.0%) to $50.58 on light volume. Thus far, 352,228 shares of Sanofi exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $50.51-$50.78 after having opened the day at $50.74 as compared to the previous trading day's close of $51.07.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $135.0 billion and is part of the drugs industry. The company has a P/E ratio of 27.2, above the S&P 500 P/E ratio of 17.7. Shares are up 6.9% year to date as of the close of trading on Friday. Currently there are 2 analysts that rate Sanofi a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Regeneron Pharmaceuticals ( REGN) is down $2.33 (-0.8%) to $280.41 on average volume. Thus far, 323,346 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 776,900 shares. The stock has ranged in price between $279.18-$287.50 after having opened the day at $284.52 as compared to the previous trading day's close of $282.74.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $27.6 billion and is part of the drugs industry. The company has a P/E ratio of 39.6, above the S&P 500 P/E ratio of 17.7. Shares are up 65.3% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Deere & Co., Analog Devices, Mercadolibre: 'Mad Money' Lightning Round

Deere & Co., Analog Devices, Mercadolibre: 'Mad Money' Lightning Round

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

Versartis Drops on Q3 Numbers, Hires Adviser -- Biotech Movers

Versartis Drops on Q3 Numbers, Hires Adviser -- Biotech Movers

Catch of the Day: Cramer's 'Mad Money' Recap (Wednesday 10/11/17)

Catch of the Day: Cramer's 'Mad Money' Recap (Wednesday 10/11/17)

Walgreens Boots Alliance, Snap, Teva: 'Mad Money' Lightning Round

Walgreens Boots Alliance, Snap, Teva: 'Mad Money' Lightning Round